The Botnar Institute of Immune Engineering (BIIE) has formalized a strategic research collaboration with Vienna-based Graph Therapeutics, an AI-driven precision immunology company co-founded by BIIE Faculty member Berend Snijder.
The agreement creates a framework for joint research programs, shared resources, and co-funded positions focused on developing immune therapies for pediatric diseases.
Combining AI and Immune Engineering
The partnership combines BIIE's primary immune modeling capabilities with Graph's AI platform that integrates patient-derived disease models with machine learning. Focus areas include computational modeling and identification of novel therapeutic targets for immune-mediated diseases affecting children globally.
"This collaboration exemplifies BIIE's commitment to building sustained partnerships that advance our mission of developing immune engineering solutions for children globally," says BIIE CEO Stephen Wilson, PhD. "Rather than traditional technology transfer models, we're creating an ongoing partnership where both organizations strengthen each other's capabilities to translate discoveries into real-world solutions for pediatric patients worldwide."
"Graph's approach to combining primary patient disease models with advanced AI represents the translational innovation needed to bridge laboratory discoveries and clinical impact," says Berend Snijder. "This collaboration will transform how we develop therapies for patients with immune-mediated diseases."
Mission-Aligned Partnership
The agreement includes provisions for jointly funded researchers, collaborative publications, and intellectual property arrangements aligned with BIIE's commitment to ensuring access for low- and middle-income countries.
More information is available in the full press release.
